These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9952194)

  • 21. Costs of coronary restenosis (Lovastatin Restenosis Trial).
    Gilbert SP; Weintraub WS; Talley JD; Boccuzzi SJ
    Am J Cardiol; 1996 Jan; 77(2):196-9. PubMed ID: 8546093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.
    Downs JR; Clearfield M; Tyroler HA; Whitney EJ; Kruyer W; Langendorfer A; Zagrebelsky V; Weis S; Shapiro DR; Beere PA; Gotto AM
    Am J Cardiol; 2001 May; 87(9):1074-9. PubMed ID: 11348605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Girman CJ; Rhodes T; Mercuri M; Pyörälä K; Kjekshus J; Pedersen TR; Beere PA; Gotto AM; Clearfield M;
    Am J Cardiol; 2004 Jan; 93(2):136-41. PubMed ID: 14715336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines.
    Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM
    Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Downs JR; Beere PA; Whitney E; Clearfield M; Weis S; Rochen J; Stein EA; Shapiro DR; Langendorfer A; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):287-93. PubMed ID: 9264420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scandinavian simvastatin study (4S).
    Grodos D; Tonglet R
    Lancet; 1994 Dec 24-31; 344(8939-8940):1768. PubMed ID: 7997017
    [No Abstract]   [Full Text] [Related]  

  • 27. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extending the benefit of lipid-regulating therapy to primary prevention.
    Jones PH; Gotto AM
    Am J Cardiol; 1995 Sep; 76(9):118C-121C. PubMed ID: 7572680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effective treatment of hypercholesterolemia.
    Parsons WB
    Arch Intern Med; 1998 Aug 10-24; 158(15):1723-4. PubMed ID: 9701113
    [No Abstract]   [Full Text] [Related]  

  • 32. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
    Ridker PM; Rifai N; Clearfield M; Downs JR; Weis SE; Miles JS; Gotto AM;
    N Engl J Med; 2001 Jun; 344(26):1959-65. PubMed ID: 11430324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scandinavian simvastatin study (4S).
    Smith GD; Pekkanen J
    Lancet; 1994 Dec 24-31; 344(8939-8940):1766; author reply 1767-8. PubMed ID: 7864990
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic and pleiotropic effects of statins in primary and secondary prevention of atherosclerosis].
    Bruckert E
    Bull Acad Natl Med; 2001; 185(1):49-60; discussion 60-2. PubMed ID: 11474569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary risk assessment methods and cholesterol lowering.
    Smith GD; Ebrahim S
    Lancet; 1999 Mar; 353(9158):1097. PubMed ID: 10199372
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic benefits of aggressive lipid lowering: a managed care perspective.
    McKenney JM; Kinosian B
    Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Where to draw the line using statins: lessons from 4S to AFCAPS/TexCAPS.
    Sprecher DL
    Cleve Clin J Med; 2000 Mar; 67(3):169-71. PubMed ID: 10743305
    [No Abstract]   [Full Text] [Related]  

  • 38. Secondary prevention in coronary heart disease. Fact: lowering cholesterol saves lives.
    McKenna CJ; Sugrue DD
    Ir Med J; 1995; 88(6):191. PubMed ID: 8575912
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
    Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
    Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.